Scandion Oncology, a spinout from the biotech company Saniona, offers experienced leadership and big hopes for the company’s cancer drug based on channel/ion inhibitors. The drug has already undergone four clinical Phase I trials and Scandion Oncology plans two Phase II trials with cancer patients within two years.